Drug profile · INN
bendroflumethiazide
NADOLOL AND BENDROFLUMETHIAZIDE
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
bendroflumethiazide (NADOLOL AND BENDROFLUMETHIAZIDE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN bendroflumethiazide
Brand NADOLOL AND BENDROFLUMETHIAZIDE
Route ORAL
Formulation TABLET
Frequently asked questions
What is bendroflumethiazide?
bendroflumethiazide (NADOLOL AND BENDROFLUMETHIAZIDE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for bendroflumethiazide?
NADOLOL AND BENDROFLUMETHIAZIDE is a marketed brand name for bendroflumethiazide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bendroflumethiazide?
bendroflumethiazide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.